spacer
home > > spring 2002 > global parallel trade - a growing concern
PUBLICATIONS


Global Parallel Trade - A Growing Concern

In an industry traditionally confined to Europe, evidence suggests that parallel trade is now expanding globally. This relatively young, yet highly controversial industry sector is breaking free from the confines of the EU and is taking a foothold in non-EU countries such as Russia, South Africa, India, and the Philippines, according to a new report published by Reuters Business Insight. Within the EU, parallel trade is also shown to be expanding as a result of increased numbers of parallel import licences granted, EU enlargement, national cost-containment drives on drug spending, and litigation victories for parallel traders - activities that are forecast to drive the parallel trade market to a US$7.4 billion industry by 2006. In The Global Parallel Trade Outlook, 2001-2006, new trends in parallel trade are identified along with potential new market opportunities that the industry has created under the current political, legal and regulatory framework of 27 countries. The report's author provides a short commentary on how parallel trade is expanding and what this could mean for the global pharmaceutical industry.

In the EU, parallel trade or parallel distribution has been a legitimate industry since the 1970s, when drugs were bought from low-priced countries and sold in high-priced countries despite the availability and distribution of locally manufactured equivalents in the import and export countries. There are a number of advantages and disadvantages to parallel trade. The most obvious and important is the financial reward from selling cheaply purchased drugs to higher priced economies. In addition, parallel trade stimulates competition and benefits the health care provider and patient through lower drug prices. The downside, however, includes the loss of revenue for the manufacturer, erosion of domestic sales, and not least is the point that parallel trade is a highly litigious practice costing firms millions of dollars each year.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tim Atkinson, Independent Biopharmaceutical Analyst

Tim Atkinson BSc (Hons), a former Biomedical Scientist and Medical Editor and Writer, has worked for over 10 years in scientific and medical publishing environments. He has written on a number of industry-related topics ranging from pharmaceutical e-commerce to drug delivery and biomaterials. He is currently working as an independent Biopharmaceutical Analyst on assignments for companies such as Reuters Business Insight and IMS Health where he has produced in-depth market intelligence business and health care reports aimed at senior executives in the pharmaceutical industry. With over 15 publications to date, Tim is currently researching and writing on lifestyle drugs and innovation in R&D.

spacer
Tim Atkinson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

PCI Pharma Services

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective and efficient clinical trials. Securing a stable supply chain to deal with the uncertainties of clinical trials is critical. One misstep can have a profound impact not only on the cost and time of your trial but also on its overall success.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement